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Purpose: To assess the knowledge and awareness of pregnant women regarding the use of sulfadoxine-
pyrimethamine (SP) for intermittent preventive therapy (IPT) and artemether-lumefantrine (ALu) for treatment 
of malaria during pregnancy.  
Methods: The study was conducted in Rufiji district, southern Tanzania from March 2011 to September 2011. 
Four hundred and seventy (470) pregnant women in their second and third trimesters were interviewed when 
attending antenatal clinics at the selected hospitals, health centers and dispensaries. Focus group discussions 
(FGDs) were also conducted with 46 pregnant women at the health facilities in the district.  
Results:  More than half (54.3 %) of pregnant women did not know if SP it was used for IPT. Most women 
(76.6 %) did not know the use of SP for IPT in relationship with gestation age. Overall, the results show that 
most women had very low knowledge about the use of SP for IPT. Forty three (9.1 %) pregnant women 
reported to have had malaria during their current pregnancies. The antimalarials reported to be used by 
pregnant women were quinine 18(42.9 %), SP (23.8 %), ALu (21.4%) and sulphamethoxyprazine-
pyrimethamine (2.4%). Irrespective of the gestation age of pregnancy, almost all  (98.3 %) pregnant women 
perceived ALu as unsafe drug to be used during pregnancy. 
Conclusion: Most pregnant women had minimum knowledge about the use and benefits of SP for IPT and 
ALu for treatment of malaria during pregnancy. Some erroneous beliefs about the safety of ALu during 
pregnancy were also identified among pregnant women. For effective implementation of IPT policy and 
treatment of malaria during pregnancy, pregnant women should be sensitized and educated on the use and 
benefits of antimalarial drugs.   
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INTRODUCTION 
 
Treatment with artemisinin combination 
therapies (ACTs) in the first trimester is not 
recommended because of concerns raised 
by animal experiments which suggested that 
artemisinin and its derivatives might be 
teratogenic and cause foetal resorption if 
given to experimental animals during a 
narrow time window in early gestation. 
Studies have confirmed embryotoxic effects 
of artemisinin and its derivatives in animals, 
including primates, with risk being confined to 
a defined period of gestation [1]. The 
teratogenic effect is thought to involve red 
blood cells production (erythropoiesis), which 
implies the human sensitive period would be 
within the first trimester of pregnancy [2]. 
Compared to other previously used 
antimalarial drugs such as chloroquine and 
sulfadoxine-pyrimethamine (SP), ALu is also 
perceived by some people as unsafe 
antimalarial drug to be used by pregnant 
women [3]. ALu has a complicated 3-days 
dosage regimen given at the intervals of 12 h 
after the first two loading doses, a factor that 
may lead to non-adherence to the full dose of 
the drug by patients [4]. 
 
SP administered in the 2nd and 3rd trimesters 
has consistently been shown to be safe and 
effective for protection against peripheral and 
placental infection and anemia during 
pregnancy and as well as reducing the 
incidence of low birth weight [4]. Women in 
areas with stable, endemic malaria 
transmission should receive two to three 
doses of SP as intermittent prevent therapy 
(IPT). WHO recommends at least 2 doses of 
sulfadoxine (500mg) and pyrimethamine 
(25mg) to be given to pregnant women after 
fetal quickening with each dose given not 
less than one month apart, and all given prior 
to the last month of pregnancy [5]. In 
Tanzania, IPT policy for pregnant women 
was adopted since August 2001 whereby it is 
recommended to give two doses of SP for 
IPT. The first dose is given during the 20th 
week of pregnancy and the second dose is 
given between the 30th and 36th week under a 
directly observed therapy.  
A number of challenges which can either be 
contributed by pregnant women, health care 
providers or poor health care system are 
likely to affect the effective implementation of 
using SP for IPT under direct observed 
therapy at the health facilities. These may 
include unreliable supply of free SP at the 
antenatal clinics and shortage of clean and 
safe water at the health facility.  Due to lack 
of clean and safe water at the health facility, 
in some cases pregnant women are given SP 
to be taken at home. This obviously does not 
guarantee adherence to treatment, and it 
would have been better if these pregnant 
women would be asked to bring clean water 
at the antenatal clinics to ensure that SP is 
taken under direct observed therapy [6]. Poor 
quality of health care services, shortage of 
staff and the long distances to antenatal 
clinics are also contributing factors for poor 
attendance of pregnant women at the 
antenatal clinics.  
 
Following antimalarial policy change in 
Tanzania it was reported that coverage for 
the use of SP was declining, whereby the first 
dose of IPT with SP in 2005 was 71% and 
declined to 65% in 2007. The second dose 
coverage was 38% in 2005, but declined to 
30% in 2007 [7]. For effective implementation 
of IPT policy it is therefore important to 
encourage pregnant women to regularly 
attend antenatal clinics. In addition, health 
care providers at the antenatal clinics should 
provide adequate information about the use 
and benefits of SP for IPT. Pregnant women 
should therefore be informed about the 
standard dosage of SP and the need to 
complete the prescribed courses. Pregnant 
women should also be counseled about 
unnecessary fear of SP-induced side effects 
including Steven-Johnson Syndrome [6].  
 
This study was designed to assess the level 
of knowledge and the acceptance of 
pregnant women regarding the use of ALu as 
the drug of choice for treatment of 
uncomplicated malaria during pregnancy, 
and the continued use of SP for IPT after it 
has been replaced by ALu as the drug of 
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choice for treatment of malaria. In addition, 
pregnant women-related factors and other 
factors that may hinder effective 
implementation of IPT using SP and malaria 
treatment in pregnancy using ALu were 




Study site  
 
The study was conducted from March 2010 
to September 2011 in Rufiji district. Rufiji 
district lies in southern Tanzania about 178 
km south of Dar-es-Salaam, the country's 
commercial capital and the biggest city in the 
country. According to the Rufiji demographic 
surveillance studies in 2008, the district had a 
population of 47,935 females of child-bearing 
age.  
 
Rufiji was selected as the study site based on 
the routine health records collected across 
the country regarding information on disease 
patterns for the purpose of health policy 
planning and monitoring. The records show 
that the district has one of the highest rates 
of outpatient consultations for malaria in the 
country (826 diagnoses per annum per 1,000 
populations), hence a malaria endemic area 
[8]. It is for this reason Rufiji was selected as 
the study site, also the area being largely 
rural with a peri-urban environment it can be 
used to represent rural and urban areas in 
Tanzania. The population of Rufiji is 
clustered around Utete (District 
headquarters), Ikwiriri, Kibiti and Bungu 
townships. The district has a total of 62 
health facilities, including 2 hospitals, 5 
health centers and 55 dispensaries. Of the 
two hospitals one is a district hospital located 
at Utete town (the district headquarter) and 
the other is Mchukwi Mission Hospital run by 
the Pentecost Church of Tanzania. 
 
Study design, population and sampling  
 
The design of the study was cross sectional 
which employed both quantitative and 
qualitative research methods. The study 
population was pregnant women attending 
antenatal clinics. Cluster sampling was used 
for selection of health facilities. The health 
facilities were divided into three clusters, 
including hospitals, health centers and 
dispensaries. All hospitals and health centers 
in the district were included in the study. A 
random sample of 8 dispensaries was 
selected using simple random sampling. 
Study participants comprised of 470 pregnant 
women who were attending antenatal clinics 
during the time of interviews. In addition, 46 
pregnant women were involved in the focus 
group discussions (FGDs).  
 




Data collection was mainly carried out by the 
researchers with the help of four trained 
nurses working at the antennal clinics in 
Rufiji. A Semi-structured questionnaire 
written in Kiswahili was used to assess the 
level of knowledge of pregnant women 
regarding the use of SP for IPT and ALu for 
treatment of malaria during pregnancy. 
Regarding IPT policy, the main focus was on 
benefits of using SP during pregnancy, 
dosage regimen, rationale for taking SP 
under observed treatment therapy and the 
importance of early attendance to the 
antenatal clinics.  Views on the efficacy and 
safety of SP use to the unborn baby and the 
mother were also sought from pregnant 
women.  
 
Regarding use of ALu for treatment of 
malaria, the focus was on the awareness and 
acceptance for its use as the antimalarial 
drug of choice for pregnant women after the 
first trimester. In addition, dosage schedule 
and necessity of meals before ALu intake 
with special focus on the use of fatty meals 
when using ALu to increase drug absorption 
were also assessed. The perceptions of 
pregnant women regarding multiple doses of 
ALu, its efficacy and safety to the unborn 
baby were also sought.  
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A knowledge scale was developed and used 
to assess the level of knowledge of pregnant 
women regarding the use of SP for IPT. The 
scale was based on six questions that were 
designed to assess the knowledge of 
pregnant women for timing and correct use of 
SP for IPT. One point was awarded for a 
correct answer and zero point for a wrong 
answer. Pregnant women’s knowledge was 
then assessed as very low (0 – 1 score), 
medium (2 – 3 score) and high (4 – 6 score).  
 
Focus group discussions  
 
Focus group discussions (FGDs) were 
conducted by a social scientist and the 
researchers using prepared guided format 
containing probes based on the objectives of 
the study. Four FGDs were conducted, two at 
the hospitals and the other two at the health 
centers. There were at least ten participants 
in each focus group. Participants were 
pregnant women attending antenatal clinics 
at the health centers and hospitals. Selection 
of participants took into account a mix of 
pregnant women with different socio-
demographic characteristics that were 
regarded to be important determinants of 
pregnant women`s knowledge and 
awareness regarding the use of SP and ALu 
for treatment of malaria and IPT, 
respectively. These included level of 
education, current trimester, gravida, marital 
status and occupation. The main themes for 
FGDs were on the importance of early 
antenatal attendance, the use of SP for IPT, 
the use of ALu for malaria treatment in 
pregnant women and other pregnant women-
related factors that are likely to affect 
implementation of IPT policy using SP and 




Data were coded and entered in the 
computer for analysis using statistical 
package for social sciences (SPSS) program 
version 16, and microsoft excel was used for 
analysing of multi-response data. Chi-square 
test was used to compare the knowledge of 
pregnant women against social demographic 
factors such as marital status, age, gravid, 
education level and occupation. The level of 
knowledge of pregnant women was also 
tested against the attendance of pregnant 
women at the antenatal clinics. A p-value of < 
0.05 was regarded as significant association 





Permission to conduct the study at the 
selected health facilities was obtained from 
Rufiji district medical officer in-charge. The 
study was granted ethical clearance from 
Muhimbili University of Health and Allied 
Sciences Research and Publications 
Committee. Oral informed consent was 
solicited in advance of data collection. Study 
participants were requested to participate 
and asked for their consent following an 




Out of the 470 women who were interviewed, 
227 (48.3 %) were in the second trimester 
and 243 (51.7 %) were in the third trimester 
of pregnancy.  More than half 258 (54.9%) of 
these women were multigravidae who have 
had 3 or more pregnancies at the time of 
interview.  Most 273 (58.1 %) of the 
participants were in the age group of 20 - 35 
years, and 58.1 % of all women had attained 
formal education.  Two hundred and thirty six 
(50.2 %) respondents were self-employed 
(farmers, pastoralists and petty business), 
and 229 (48.7%) were housewives (Table 1).   
 
Knowledge of pregnant women regarding 
the use of SP for IPT  
 
Only 110 (23.4 %) of pregnant women 
correctly understood that early antenatal 
clinic attendance enables women to get the 
recommended courses of SP for IPT on time. 
Others reported health checkup (42.6 %), 
counseling (17.7 %), vaccination (2.8 %) and 
treatment of various health conditions 
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(13.6%) as the benefits of early antenatal 
clinic attendance.  
 
Table 1: Socio-demographic characteristics of 
pregnant women who were recruited in the study 















Education   
No formal education 197 41.9 






More than primary education 17 3.6 
Current trimester   
Second 227 48.3 
Third 243 51.7 
Gravida   
First pregnancy 120 25.5 
Second pregnancy 92 19.6 
Third or more pregnancy 258 54.9 
Marital status   
Married 370 78.7 
Unmarried 92 19.6 
Cohabiting/Divorced 8 1.7 
Occupation   
House wife 229 48.7 
Self employed 236 50.2 
Employed 5 1.1 
 
Pregnant women were also interviewed 
about their awareness of the different 
methods that have been advocated for 
prevention of malaria in pregnant women.   
 
A hundred and fifty one (32.1 %) pregnant 
women mentioned the use of SP for IPT as 
one of the methods for protecting pregnant 
women from malaria. Others mentioned 
untreated bed nets (31.1 %), insecticide-
treated bed nets (36.6 %) and indoor 
spraying with insecticides (0.2 %). Although 
251 (53.3 %) pregnant women reported to 
have used SP when visiting antenatal clinics, 
most women did not know the advantages of 
using SP when pregnant.  Two hundred and 
fourteen (45.5 %) pregnant women were 
aware that SP is given for IPT purpose. As 
an indication that pregnant women did not 
know why they were given SP, one of the 
participants in the focus group at Mohoro 
health centre said:  
 
“We were given three tablets and we were 
told to swallow them in front of the nurse, but 
we do not know why we were given those 
tablets.” 
 
In terms of the number of SP tablets to be 
taken for IPT, 245 (52.1 %) pregnant women 
mentioned that 3 tablets should be taken at 
once, 4 (0.9 %) mentioned 2 tablets and the 
rest 221 (47 %) did not know how many 
tables should be taken. It was only 91 (19.4 
%) pregnant women who knew that 2 doses 
of SP are given for IPT, whereas 220 (46.8 
%) did not know and the rest 158 (33.6 %) 
said that one dose of SP should be given. 
Only 80 (17 %) pregnant women mentioned 
that SP is given during the 2nd and 3rd 
trimesters, although they were also unable to 
indicate the exact weeks during which SP 
should be taken. Others did not know the 
correct timing of SP, with some women 
mentioning only the 2nd trimester (29.6 %), 
third trimester (6 %), first trimester (0.2%), 
and all the three trimesters of pregnancy (0.2 
%). The rest, 221 (47 %) pregnant women 
were unable to mention the trimester during 
which SP should be provided. With regard to 
direct observation therapy for SP, 232 (49.4 
%) pregnant women mentioned that SP is 
taken under direct observation therapy to 
improve compliance, 221 (47 %) did not 
know and 17 (3.6 %) indicated that it is taken 
at home.  
 
According to the knowledge scale based on 
the range of the answers provided by 
pregnant women for the correct use of SP for 
IPT, it is shown that 210 (44.7 %) pregnant 
women  had very low knowledge, 117 (24.9 
%)  had moderate knowledge and 143 (30.4 
%) had high level of knowledge. The level of 
knowledge regarding use of SP for IPT 
correlated with age (p = 0.005), gravida (p =  
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Table 2: The levels of knowledge about IPT policy using SP with respect to marital status, age and gravida 
of pregnant women (N = 470) 
 
Knowledge level Characteristic  
Very low Medium High 
Marital status    
Single 177 (37.7%) 77 (16.4%) 116 (24.7%) 
Married 31 (6.6%) 35 (7.4%) 26 (5.5%) 
Co-habiting/widowed 2 (0.41%) 5 (1.1%) 1 (0.2%) 
Age    
<30 years 158 (33.6%) 91 (19.4%) 88 (18.7%) 
>30’s years 52 (11.1%) 26 (5.5%) 55 (11.7%) 
Gravida    
Primigravida 51 (10.9%) 40 (8.5%) 29 (6.2%) 
Multigravida 159 (33.8%) 77 (16.4%) 114 (24.3%) 
 
Table 3: Frequency of attendance to the antenatal clinics as reported by pregnant women during interviews 
(N = 470) 
 
Variable N % 













   
Gestation age (weeks) when attending ANCs* 
for the first time 
  
4 – 15 88 18.7 
16 – 27 356 75.7 
28 and above 26 5.5 
   *Antenatal Clinics 
 
0.032) and marital status (p = 0.001) of the 
pregnant women (Table 2). 
 
Factors affecting implementation of IPT 
policy using SP 
 
The study explored a number of women 
related factors which could be affecting the 
implementation of IPT policy using SP, 
including attendance of pregnant women at 
the antenatal clinics. Almost two thirds 288 
(61.2%) of pregnant women started attending 
antenatal clinics after 20 weeks of gestation 
(Table 3).  
 
During the day of interview, 179 (38.1 %) 
pregnant women were attending antenatal 
clinics for the second time (Table 3). The rest 
141 (30%) were attending antenatal clinics 
for the first time, 105 (22.3 %) for the third 
time and 45 (9.6%) for the fourth or more 
times. There was an association between the 
level of knowledge about IPT policy using SP 
and the number of antenatal clinic visits by 
pregnant women (p = 0.041) (Table 4). 
 
Pregnant women were asked if they had 
taken SP for IPT for their current 
pregnancies. It was reported that 220 (46.8 
%) pregnant women had not taken SP, 157 
(33.4 %) had taken a single dose, 92 (19.4 
%) had taken two doses and 1 (0.2 %) 
reported to have been given three doses of 
SP when pregnant. The number of SP doses 
taken had an association with the level of 
knowledge of pregnant women for IPT policy 
using SP (p < 0.0001). Out of 220 pregnant 
women who had not been given SP during  
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Table 4:  Levels of knowledge of respondents about IPT policy using SP in relation to the number of 
antenatal clinic visits they had made (N = 470). 
 
Visit  Level of knowledge 
1st    2nd  3rd  ≥4th  
Very low  72(15%) 86(18.3%) 34(7.2%) 18(3.8%) 
Moderate 37(7.9%) 41(8.7%) 28(6.0%) 11(2.3%) 
High 32(6.8%) 52(11.1%) 43(9.1%) 16(3.4%) 
Total 141(30.0%) 179(38.1%) 105(22.3%) 45(9.6) 
 
 their current pregnancies, 214 (97.3 %) of 
them reported that the medication was out of 
stock when they attended antenatal clinics, 2 
(0.91 %) refused to take the medication and 4 
(1.82 %) did not attend the clinics on the day 
they were to be given the tablets. During the 
focus group discussion, a 45 years old 
pregnant woman at Utete district hospital 
said:  
 
“Today I was supposed to take a dose of SP 
but when I came here I was told that the drug 
was out of stock. I was then told to buy the 
tablets from the neighboring pharmacy and 
then bring them to the clinic to be taken 
under direct observed therapy”. 
 
Pregnant women were asked to mention the 
measures they take when SP is out of stock 
at the antenatal clinics.  Most (94.1 %) 
pregnant women reported that they do 
nothing, whereas 28 (5.9 %) said they would 
go to another health facility to look for SP if 
they are directed by the nurse. Other factors 
reported by pregnant women to be affecting 
the implementation of IPT policy include lack 
of bus fare to attend antenatal clinics (5.3 %) 
and unavailability of reliable transport to the 
health facilities (1.9 %).  
 
In assessing acceptability of SP for IPT, 
pregnant women were asked to provide their 
views regarding SP-induced side effects and 
its tolerability.  Two hundred and thirty one 
(49.1 %) pregnant women said that the 
tablets are well tolerated, while 222 (47.2 %) 
did not know any SP-induced side effects and 
could therefore not provide any response.  It 
was only 16 (3.4 %) pregnant women who 
reported to have had experienced SP-
induced side effects including rashes (12.5 
%), fever (25 %), headache (12.5 %) and 
stomach cramps (50 %). During the focus 
group discussion, a middle-aged 
multigravidae woman at Ikwiriri mission 
reported: 
 
“There were women who took SP on an 
empty stomach and started vomiting, they felt 
dizzy and became weak.  Due to this 
problem, some women would not take SP, 
unless it is given under directly observed 
therapy at the health facility.”  
 
During the focus group discussions it was 
learnt that issues such as cost sharing, 
scarcity of health care providers, and long 
distances travelled to the health facilities are 
the main causes for poor attendance of 
pregnant women to antenatal clinics. As a 
result, this affects timely provision of SP for 
IPT to pregnant women. Family 
responsibilities including taking care of young 
children was commented to be another 
reason for pregnant women not attending 
antenatal clinics on time. In some health 
facilities pregnant women were required to go 
to the antenatal clinics with their spouses. 
This was seen to be a challenge since many 
husbands are usually not willing to escort 
their spouses to the clinics.  
 
The use of ALu as the drug of choice for 
treatment of malaria during pregnancy 
 
Out of 470 pregnant women who were 
interviewed, 43 (9.1 %) have had episode(s) 
of malaria fever during their current 
pregnancies.  It was only 9 (1.9 %) pregnant 
women who reported to have used ALu for 
treatment of malaria.  Out of 9 women who 
reported to have used ALu when pregnant, 3 
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(0.6 %) were in the first trimester of 
pregnancy. All 470 women did not know the 
gestation period in which ALu is indicated for 
treatment of malaria in pregnant women. 
During focus group discussions, most women 
mentioned that ALu is not safe to be used by 
pregnant women. This was echoed by a 27 
year-old multigravidae participant at Ikwiriri 
mission, who said: 
  
“I got malaria when I was 5 months pregnant, 
but I was told by the nurse that I cannot take 
ALu until the pregnancy was 7 months old. I 
was therefore given sulphamethoxyprazine-
pyrimethamine.”   
 
Only a small proportion (1.9 %) of pregnant 
women knew the correct dose and dosage 
regimen of ALu. Among those who knew the 
correct dose and dosage regimen of ALu, 
only 8 (1.7 %) pregnant women knew that 
ALu should not be taken in an empty 
stomach. Two multigravidae participants who 
had used ALu when pregnant mentioned the 
dosage of ALu that were prescribed to them. 
One of them mentioned that she was told to 
take four tablets of ALu after every 8 h till she 
finishes 24 tablets. The other participant said 
that she was told to take four tablets at 
2:00pm then another four tablets at 10:00pm, 
and then take the rest of the doses after 
every twelve hours for two consecutive days.  
 
Quinine was mentioned by 202 (42.9 %) 
pregnant women as the most commonly used 
drug, followed by SP (23.8 %), ALu (21.4 %) 
and sulphamethoxyprazine-pyrimethamine) 
(2.4 %). Forty five (9.5%) pregnant women 
could not remember the names of 
antimalarial drugs that they used when 
pregnant. In the focus group discussions it 
was reported that the commonest diseases 
that cause death to pregnant women in Rufiji 
were malaria, eclampsia, anaemia, post 
partum hemorrhage and heavy bleeding 
when pregnant.  Most referral hospitals are 
far from where most of the residents reside, 
and therefore some deaths are mainly due to 
delays in referring patients to hospitals with 
qualified health care personnel and adequate 
facilities for diagnosis and treatment.  
DISCUSSION  
 
The results obtained show that almost half of 
the pregnant women had very low knowledge 
regarding the importance of IPT. Majority of 
pregnant women did not know why SP was 
provided, the correct timing of IPT and 
number of SP doses that are required for IPT 
during pregnancy. During focus group 
discussions it was evident that health care 
workers did not adequately sensitize and 
counsel pregnant women regarding the use 
of SP for IPT. These findings are similar to 
those previously reported by other 
researchers indicating that there is poor 
dissemination of information on the 
importance of IPT policy using SP among 
stakeholders including pregnant women in 
Tanzania [6].  
 
The guidelines for maternal and child health 
stipulate that the first visit should be at the 
16th week, second visit at 20-24th, third visit at 
28-32nd week and the fourth visit at 36-40th 
week of gestation [4]. In this study, about 
two-third of pregnant women started 
attending antenatal clinics at 16 weeks or 
more of gestation. Because of late and 
irregular attendance to antenatal clinics, a 
large number of pregnant women did not 
receive the recommended two doses of SP 
for IPT at the pre-determined times. A similar 
study that was conducted in Uganda in 2010 
also indicated that late and irregular 
attendance to antenatal clinics disrupt 
antenatal schedules for proper delivery of IPT 
[9]. In the present study, pregnant women 
who had attended antenatal clinics for at 
least 3 times had better knowledge on IPT 
policy compared to those who had attended 
once or twice, suggesting an association 
between the number of antenatal visits and 
the level of knowledge on IPT policy among 
pregnant women. 
 
It was also observed that there is an 
association between marital status, age and 
gravida of a woman and the level of 
knowledge on IPT policy. Majority of single 
pregnant women had very low knowledge 
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compared to married ones. Results obtained 
from focus group discussions indicated that 
married women did get extra support from 
their spouses for attending antenatal clinics 
and subsequent use of SP for IPT. It was 
also observed that there has been increased 
sensitization at the antenatal clinics in most 
of the health facilities encouraging pregnant 
women to attend the clinics with their 
spouses so as to improve health education 
and support of pregnant women at the family 
level. This practice should be encouraged as 
it appears to have positive outcome on the 
overall health care given to pregnant women 
at the antenatal clinic and at home. The 
results also show that overall, older pregnant 
women had better understanding of IPT 
policy than the younger ones. In addition, 
multigravidae were more knowledgeable than 
primigravidae women regarding IPT. Similar 
to the findings of this study, other studies 
have also reported that age of the pregnant 
woman, time of registration with an antenatal 
provider, gravida and transport facilities 
available in the village were important 
predictors significantly affecting the utilization 
of minimum recommended antenatal care 
services [9, 10]. These results indicate the 
need to have sensitization programs that that 
are designed to target different groups of 
pregnant women at the antenatal clinics.  
 
For successful provision of IPT in pregnant 
women, it is imperative to ensure adequate 
and uninterrupted availability of SP at the 
health facilities [11, 12]. In this study, 
unavailability of SP was the main reason for 
about 50% of pregnant women not to have 
taken SP for IPT at the health facilities. 
These findings support the hypothesis that 
poor quality of healthcare services such as 
unavailability of medications and other basic 
services contribute to poor attendance of 
pregnant women at antenatal clinics [6].  
 
Unless the benefits outweigh the risks, it is 
recommended that artemisinin should not be 
used in the first trimester of pregnancy 
because of its teratogenic effects including 
foetal resorption [13]. In the present study, 
about a quarter of pregnant women who were 
given ALu for treatment of malaria were in the 
first trimester of pregnancy. As shown by 
recent studies, the main reason for irrational 
use of antimalarial drugs in Tanzania is the 
lack of knowledge among health care 
providers [14,15]. It has also been reported 
that some pregnant women do not 
understand the instructions given by drug 
dispensers regarding the dosage and 
duration of use of ALu [3].  
 
Lack of knowledge of antimalarial drug use 
during pregnancy is a serious problem, 
especially in areas of intense transmission 
such as Rufiji and other parts of Tanzania, 
where antimalarial drugs are given repeatedly 
to treat frequent fevers (even in the absence 
of malaria), thus increasing the risk of 
resistance and adverse drug reactions [14]. 
Due to lack of proper counseling of patients 
by health care providers about the benefits of 
ALu for the treatment of malaria, other 
pregnant women preferred using other 
antmalarial drugs such as sulphamethoxy-
prazine-pyrimethamine and SP which have 
been ruled out for the treatment of malaria in 
Tanzania. Unlike SP which was taken as a 
single dose for treatment of malaria, ALu is a 
multi-dose regimen taken over a period of 
three days. For many patients, this makes 
adherence a problem.  
 
Limitations of the study 
 
Participants in this study were pregnant 
women who were attending antenatal clinics. 
Due to the fact that some pregnant women 
may not be attending antenatal clinics, the 
overall knowledge and awareness of 
pregnant women regarding use of SP for IPT 
and ALu for treatment of malaria may be 
even much lower in Rufiji district. Due to the 
small sample size of both facilities and 
respondents in this study, the data on the 
knowledge and awareness about IPT and 
use of ALu among pregnant women reported 
here is limited in its generalizability beyond 
the study population. However, antenatal 
Mutagonda et al 
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clinics were selected to represent a range of 
settings and levels of health facility, and 
sampling was done randomly in the district 
and therefore may have minimized source of 
bias. In addition, the national guidelines 
determining the timing of delivery of IPT and 
use of ALu for treatment of malaria apply 
throughout Tanzania. This suggests that the 
results presented here may apply elsewhere 
in Tanzania, especially in the rural areas, and 
therefore justify the need to conduct a larger 
survey to further investigate use of SP for IPT 





Most pregnant women had below average 
level of knowledge about the use and 
benefits of SP for IPT and ALu for treatment 
of malaria during pregnancy. There is 
therefore a need to continuously sensitize 
and educate pregnant women about the use 
and benefits of antimalarial drugs.  
Sensitization programs should be designed to 
target different groups of pregnant women at 
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